Blueprint Medicines (BPMC) Misses Q3 EPS by 37c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.00), $0.37 worse than the analyst estimate of ($1.63).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• BTIG Reiterates Neutral Rating on MaxCyte Inc. (MXCT)
• BofA starts bullish Alvotech coverage on biosimilar launch cycle
• Barclays Downgrades Merlin Properties SA (MRL:SM) (MRPRF) to Equalweight